PD-007 YI High-dose Infliximab Lowers 30-Day Colectomy Rates in Hospitalized Ulcerative Colitis Patients: A Propensity-Score Weighted Analysis

    loading  Checking for direct PDF access through Ovid

Abstract

Background:

15% to 20% of ulcerative colitis (UC) patients will have a flare warranting hospitalization, with approximatey 20% progressing to colectomy. Data on predictors of rapid progression to colectomy (<30 d) are limited. Infliximab (IFX) is now common practice in the management of hospitalized UC patients but standard dosing regimens are currently based on the ACT1 and 2 trials performed in outpatient moderate-severe UC. Hospitalized UC patients have a higher inflammatory burden resulting is more rapid IFX clearance, suggesting higher up-front dosing of IFX may be needed to avoid colectomy. Our aim was to use propensity-scoring methodology to examine predictors of 30-days outcomes and determine whether initial IFX dosing strategy is associated with 30-days colectomy rates.

Methods:

This was a retrospective study of UC patients admitted or transferred to a tertiary care IBD service between January 2011 and April 2016. Inclusion criteria were: UC diagnosis confirmed prior to admission based on standard criteria; hospitalized for acute UC; IFX-naïve; and at least one induction dose of IFX administered during hospitalization. The primary outcome was 30-days colectomy rate; additional outcomes included 90 days colectomy rate, need for additional IFX within 7 days of initial infusion, length of stay (LOS), and medical and surgical complication rate. Inverse probability-weighted propensity-scores (IWPS) were constructed to account for potential selection bias between patients receiving IFX 5 mg/kg (standard group, SD) and 10 mg/kg (high-dose group, HD). Univariate and multivariate testing were performed.

Results:

146 patients were analyzed, 120 SD and 26 HD. HD patients were younger (35 [16–82] versus 22 [8–86] yr), otherwise the groups were similar in terms of demographics, baseline disease characteristics, and former/current non-IFX anti-TNF use. Mean admission CRP was higher in the SD versus HD group (68 versus 37.8 mg/L), but other parameters including albumin and hemoglobin (hb) nadir were similar. Twenty-five patients underwent colectomy by 30 days (17.1%) and 33 patients by 90 days (22.6%). Fewer patients in the HD group (15.4%) underwent colectomy versus the SD group (17.5%) at 30 days (P < 0.001). Twenty-two patients in the SD group compared to 0 patients in the HD group needed an additional IFX dose within 7 days of the first IFX infusion. The HD group had shorter LOS and fewer complications. Hb nadir (aOR 1.43, 1.23–1.58, P < 0.001), admission CRP (aOR 1.01, 1.00–1.02, P = 0.02), pediatric provider type (aOR 20.6, 5.4–78.7, P < 0.001), and need for additional IFX within 7 days (aOR 4.4, 1.49–13.2, P = 0.007) were independently associated with 30-days colectomy rate; receiving 10 mg/kg as the initial dose was associated with 80% lower odds of 30-days colectomy (aOR 0.20, 0.06–0.67, P = 0.009). Albumin <3 g/dL, hb nadir <8 g/dL, and CRP >10 g/dL, predicted 30-days colectomy with 91% sensitivity and 40% specificity (AUC 0.72, 0.60–0.84, P = 0.001).

Conclusions:

Up-front dosing of IFX 10 versus 5 mg/kg is associated with an 80% reduction in 30-days colectomy, fewer complications, and shorter LOS. There should be a low threshold for early colectomy instead of additional IFX if the response to the initial infusion is inadequate. Prospective studies validating our findings are needed.

Related Topics

    loading  Loading Related Articles